Vanda Pharmaceuticals, Inc. (VNDA)
5.43
+0.09
(+1.69%)
USD |
NASDAQ |
Sep 04, 16:00
5.43
0.00 (0.00%)
After-Hours: 20:00
Vanda Pharmaceuticals Enterprise Value : 180.97M for Sept. 4, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 04, 2026 | 180.97M |
| September 03, 2026 | 175.53M |
| September 02, 2026 | 187.01M |
| September 01, 2026 | 180.36M |
| August 31, 2026 | 179.16M |
| August 28, 2026 | 172.51M |
| August 27, 2026 | 181.57M |
| August 26, 2026 | 176.13M |
| August 25, 2026 | 181.57M |
| August 24, 2026 | 174.92M |
| August 21, 2026 | 171.90M |
| August 20, 2026 | 177.95M |
| August 19, 2026 | 189.43M |
| August 18, 2026 | 181.57M |
| August 17, 2026 | 170.69M |
| August 14, 2026 | 168.27M |
| August 13, 2026 | 156.79M |
| August 12, 2026 | 166.46M |
| August 11, 2026 | 150.74M |
| August 10, 2026 | 156.18M |
| August 07, 2026 | 154.97M |
| August 06, 2026 | 161.93M |
| August 05, 2026 | 160.41M |
| August 04, 2026 | 174.92M |
| August 03, 2026 | 168.88M |
| Date | Value |
|---|---|
| July 31, 2026 | 161.02M |
| July 30, 2026 | 165.86M |
| July 29, 2026 | 158.00M |
| July 28, 2026 | 164.65M |
| July 27, 2026 | 168.27M |
| July 24, 2026 | 165.86M |
| July 23, 2026 | 176.74M |
| July 22, 2026 | 176.13M |
| July 21, 2026 | 183.99M |
| July 20, 2026 | 174.32M |
| July 17, 2026 | 181.57M |
| July 16, 2026 | 182.18M |
| July 15, 2026 | 206.36M |
| July 14, 2026 | 206.36M |
| July 13, 2026 | 215.43M |
| July 10, 2026 | 229.94M |
| July 09, 2026 | 238.40M |
| July 08, 2026 | 250.49M |
| July 07, 2026 | 239.01M |
| July 06, 2026 | 229.33M |
| July 02, 2026 | 228.12M |
| July 01, 2026 | 218.45M |
| June 30, 2026 | 222.68M |
| June 29, 2026 | 179.99M |
| June 26, 2026 | 172.18M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Protagonist Therapeutics, Inc. | 8.651B |
| ACADIA Pharmaceuticals, Inc. | 3.941B |
| Alnylam Pharmaceuticals, Inc. | 35.27B |
| Anika Therapeutics, Inc. | 265.34M |
| Savara, Inc. | 960.37M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -62.51M |
| Revenue (Quarterly) | 50.53M |
| Total Expenses (Quarterly) | 113.04M |
| EPS Diluted (Quarterly) | -1.038 |
| Gross Profit Margin (Quarterly) | 89.02% |
| Profit Margin (Quarterly) | -123.7% |
| Earnings Yield | -85.19% |
| Normalized Earnings Yield | -85.19 |